Health officials see Novavax''s protein-based vaccine as a valuable alternative for people who don''t want to take messenger RNA shots from Pfizer and Moderna.

Billions of people around the world have received the Pfizer or Moderna COVID-19 vaccines. The rapid development of these vaccines changed the course of the pandemic, providing protection against the SARS-CoV-2 virus.

Amid the tumult of a turbulent market landscape, savvy investors cast a hopeful eye toward top value stocks. The Dow is down, shedding over 100 points on Friday, and both the S&P 500 and Nasdaq are wrapping up their worst month in 2023 , making the outlook appear dim for many assets. However, not all is lost in this financial tempest. For the discerning investor, this is an opportune moment to recalibrate. Consequently, redirecting their portfolio’s compass towards value stocks could prove beneficial. Whispers of gold potentially dipping into the negative in 2023 add to the growing uncertainty. Despite this, seasoned investors understand that top value stocks emerge as safe harbors in such times. They demonstrate resilience and robust growth potential. Within this milieu of financial unpredictability, exercising prudence is essential. Hence, ensure your investments are not only shielded from the ongoing storm but are also primed to flourish in the subsequent calm. By refocusing on value, investors can adeptly navigate these tumultuous times.

Hospira, Inc., owned by drug major Pfizer Inc., is recalling certain Sodium Bicarbonate and Lidocaine HCl Injections citing the potential for presence of glass particulate matter, the U.S. Food and Drug Administration said. The recall involves 4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10mL vial; 1% Lidocaine HCl Injection, USP, 50 mg/5mL vial; and 2% Lidocaine HCl Injection, USP, 100 mg/5mL.

STOCKHOLM: Hungarian scientist Katalin Karikó and her US colleague Drew Weissman have won the ''2023 Nobel Prize for Medicine'' for making the mRNA molecule discoveries. These discoveries paved the way for Covid-19 vaccines. “The laureates contributed to the unprecedented rate of vaccine development during one of the greatest threats to human health in modern times,” the Swedish award-giving body’s statement for the duo said. The prize, among the most prestigious in the scientific world, was selected by the Nobel Assembly of Sweden’s Karolinska Institute medical university and comes with 11 million Swedish crowns (about $1 million) to share between them. The winners Karikó is the former senior vice president and head of RNA protein replacement at German biotech firm BioNTech. She is also a professor at the University of Szeged in Hungary and an adjunct professor at the University of Pennsylvania (UPenn). Karikó’s history with UPenn is not a pleasant one. Karikó said that her failure to secure research grants led to UPenn demoting her from a full-time professor track in 1995.

Billions of people around the world have received the Pfizer or Moderna COVID-19 vaccines. The rapid development of these vaccines changed the course of the pandemic, providing protection against the SARS-CoV-2 virus. But these vaccines would not have been possible it if weren’t for the pioneering work of this year’s winners of the Nobel prize […] The post Nobel prize in medicine awarded to mRNA pioneers – here’s how their discovery was integral to COVID vaccine development appeared first on Philippine Canadian Inquirer .

A former Pfizer minerals business that supplied talc for cosmetic products has filed for bankruptcy to deal with hundreds of personal injury lawsuits, saying that the drug giant is increasingly unwilling to cover those claims.

STOCKHOLM: Researchers Katalin Kariko and Drew Weissman won the Nobel Medicine Prize on Monday for work on messenger RNA (mRNA) technology that paved the way for groundbreaking COVID-19 vaccines. The pair, who had been tipped as favorites, “contributed to the unprecedented rate of vaccine development during one of the greatest threats to human health in modern times”, the jury said. The World Health Organization declared COVID-19 a pandemic in March 2020 and the first mRNA vaccines were approved for use against the illness in December that year. Billions of Pfizer/BioNTech and Moderna doses have been injected around the world since then. Together with other COVID vaccines, they “have saved millions of lives and prevented severe disease in many more”, the jury said. Kariko, 68, and Weissman, 64, longstanding colleagues at the University of Pennsylvania in the United States, have already won a slew of awards for their research. In recognizing the duo this year, the Nobel committee broke with its usual practice of honoring decades-old research, aimed at ensuring it has stood the test of time.

Katalin Karikó and Drew Weissman were honored today with the Nobel Prize in medicine for their research that enabled the development of mRNA vaccines. In response, Peter Maybarduk, director of the Access to Medicines program at Public Citizen released the following statement. “The mRNA vaccines saved many lives during the COVID emergency, though disproportionately in wealthy countries through a global vaccine apartheid that left billions of people without needed medical supplies. “Many people can be grateful to the scientists and public health agencies that pioneered mRNA’s development. Yet even more people have been excluded. Today’s Nobel must ring as a call for equity and health justice, and a call to change a massively unjust pharmaceutical industry. mRNA is a transformative technology that should belong to humanity.” “Moderna, Pfizer and BioNTech still largely control the available vaccines and in some countries have significantly increased their price, despite the billions in public funding on which the vaccines rely.

With a few exceptions, pharmaceutical stocks have underperformed the broader market this year. The S&P Pharmaceutical Index is down 3% year to date versus a 12% gain in the benchmark S&P 500 . Several reasons account for the underperformance, ranging from a focus on technology stocks to the patent expirations for several blockbuster drugs. One such case is Humira, used to treat arthritis and other conditions. However, pharmaceutical stocks can be expected to eventually rebound. The good news for investors is that many pharma stocks are on sale right now and can be purchased at rock bottom prices. Let’s examine three well-positioned stocks that are expected to have a Q4 comeback. Eli Lilly (LLY) Source: Jonathan Weiss / Shutterstock.com First up, the hands-down winner among pharmaceutical stocks this year is Eli Lilly (NYSE: LLY ). So far in 2023, the company’s share price has increased 47%, bringing the stock’s five year gain to 367%. LLY stock has literally outpaced every other pharma security on the market.